arrow_back Back Filing freshness 10-Q Q1 FY2026 SEC EDGAR

Neuraxis, INC

NRXS
$7.09 ▲ +0.19 (+2.75%) at close
Healthcare ·Electromedical & Electrotherapeutic Apparatus ·USElectromedical & Electrotherapeutic Apparatus
18 Visible periods
29 Metrics
Peer-ranked Benchmarks
Price Chart
20
Health
Poor
Bearish
auto_awesome

Analytical Summary

Neuraxis, INC faces fundamental challenges with weakness in Return on Common Equity (%). The fundamentals warrant careful consideration of downside risks.

Market Cap $77.6M
Dividend Yield
Revenue Growth 79.5%
Op. Margin -108.3%
ROIC -23.9%
FCF / Share $-0.11
Trailing P/E
Price / Book 14.1x
FCF Yield
Debt / Equity 0.02
info Valuation on last close. End-of-day price, Aug 7, 2026.

18-Year Financial Trajectory

Quarterly
Metric Value Trend Year over Year Percentile
Revenue Total top-line sales
$1.61M
↑ +79.5%
Net Income Profit after all expenses
$-1.76M
↑ +22.7%
Operating Margin Operating profit as % of sales
-108.3%
↑ +39.0% 0th
FCF / Share Free cash flow per share
$-0.11
↑ +48.3%
trending_up

Bullish Indicators

  • Debt to EquityDebt to Equity is in the top quartile (lower is better)
warning

Bearish Risks

  • Operating Margin (%)Operating Margin (%) is in the bottom quartile
  • Profit Margin (%)Profit Margin (%) is in the bottom quartile
  • Return on Common Equity (%)Return on Common Equity (%) is in the bottom quartile

Health Breakdown

Profitability
1
Returns
1
Financial Health
51
Cash Quality
56

bar_chart Data from SEC EDGAR XBRL filings

Synced 1 week ago 5 years · 18 quarters